Does PALBOCICLIB Cause Ovarian hyperstimulation syndrome? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Ovarian hyperstimulation syndrome have been filed in association with PALBOCICLIB (Ibrance). This represents 0.0% of all adverse event reports for PALBOCICLIB.
9
Reports of Ovarian hyperstimulation syndrome with PALBOCICLIB
0.0%
of all PALBOCICLIB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Ovarian hyperstimulation syndrome From PALBOCICLIB?
Of the 9 reports.
Is Ovarian hyperstimulation syndrome Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Ovarian hyperstimulation syndrome?
CHORIOGONADOTROPIN ALFA (1,016)
FOLLITROPIN (718)
GANIRELIX (672)
TRIPTORELIN (356)
PROGESTERONE (293)
MENOTROPINS (238)
LUTROPIN ALFA (194)
GONADOTROPHIN, CHORIONIC (173)
FOLLITROPIN BETA (163)
FOLLITROPIN ALFA (138)
Which PALBOCICLIB Alternatives Have Lower Ovarian hyperstimulation syndrome Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID